Sareum Hldgs Plc (SAR) - Cash Flow Conversion Efficiency

Latest as of December 2025: -1.269x

Based on the latest financial reports, Sareum Hldgs Plc (SAR) has a cash flow conversion efficiency ratio of -1.269x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.51 Million ≈ $-184.33 USD) by net assets (GBX1.19 Million ≈ $145.28 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sareum Hldgs Plc market capitalisation for the company's overall valuation and market capitalisation.

Sareum Hldgs Plc - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Sareum Hldgs Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Sareum Hldgs Plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sareum Hldgs Plc ranked by their cash flow conversion efficiency. Explore Sareum Hldgs Plc (SAR) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Reliance Industries Limited
IL:RIGD
N/A
Kermode Resources Ltd
V:KLM
0.087x
Element Lifestyle Retirement Inc
V:ELM
-0.003x
Kromek Group PLC
LSE:KMK
0.026x
MAPLE LEAF GREEN WORLD
F:4HV0
0.000x
Oxford Metrics plc
LSE:OMG
0.026x
TrustBIX Inc
V:TBIX
0.061x
S2Medical AB
ST:S2M
-0.031x

Annual Cash Flow Conversion Efficiency for Sareum Hldgs Plc (2004–2025)

The table below shows the annual cash flow conversion efficiency of Sareum Hldgs Plc from 2004 to 2025. View Sareum Hldgs Plc stock quote for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 GBX2.28 Million
≈ $277.05
GBX-2.55 Million
≈ $-310.38
-1.120x +39.57%
2024-06-30 GBX2.11 Million
≈ $257.21
GBX-3.92 Million
≈ $-476.83
-1.854x +34.57%
2023-06-30 GBX1.15 Million
≈ $140.29
GBX-3.27 Million
≈ $-397.50
-2.833x -475.87%
2022-06-30 GBX4.33 Million
≈ $526.96
GBX-2.13 Million
≈ $-259.28
-0.492x +12.44%
2021-06-30 GBX2.80 Million
≈ $340.07
GBX-1.57 Million
≈ $-191.10
-0.562x -24.65%
2020-06-30 GBX1.80 Million
≈ $219.44
GBX-813.09K
≈ $-98.93
-0.451x +60.95%
2019-06-30 GBX1.09 Million
≈ $133.13
GBX-1.26 Million
≈ $-153.70
-1.154x -18.37%
2018-06-30 GBX1.63 Million
≈ $198.64
GBX-1.59 Million
≈ $-193.74
-0.975x -371.10%
2017-06-30 GBX2.35 Million
≈ $285.39
GBX843.87K
≈ $102.67
0.360x +198.88%
2016-06-30 GBX1.86 Million
≈ $226.74
GBX-678.00K
≈ $-82.49
-0.364x -5.22%
2015-06-30 GBX1.86 Million
≈ $226.69
GBX-644.24K
≈ $-78.39
-0.346x +24.16%
2014-06-30 GBX1.72 Million
≈ $209.58
GBX-785.34K
≈ $-95.55
-0.456x +65.64%
2013-06-30 GBX439.10K
≈ $53.43
GBX-582.74K
≈ $-70.90
-1.327x -5.88%
2012-06-30 GBX480.38K
≈ $58.45
GBX-602.14K
≈ $-73.26
-1.253x -100.37%
2011-06-30 GBX876.00K
≈ $106.58
GBX-548.00K
≈ $-66.68
-0.626x +37.68%
2010-06-30 GBX523.00K
≈ $63.63
GBX-525.00K
≈ $-63.88
-1.004x +54.03%
2009-06-30 GBX327.00K
≈ $39.79
GBX-714.00K
≈ $-86.87
-2.183x -81.42%
2008-06-30 GBX1.40 Million
≈ $170.34
GBX-1.69 Million
≈ $-205.02
-1.204x -579.37%
2007-06-30 GBX1.37 Million
≈ $166.20
GBX-242.00K
≈ $-29.44
-0.177x +13.59%
2006-06-30 GBX1.20 Million
≈ $145.40
GBX-245.00K
≈ $-29.81
-0.205x +82.42%
2005-06-30 GBX1.32 Million
≈ $160.48
GBX-1.54 Million
≈ $-187.13
-1.166x -2128.90%
2004-06-30 GBX-87.00K
≈ $-10.59
GBX-5.00K
≈ $-0.61
0.057x --

About Sareum Hldgs Plc

LSE:SAR UK Biotechnology
Market Cap
$505.78K
GBX4.16 Billion GBX
Market Cap Rank
#31063 Global
#927 in UK
Share Price
GBX30.00
Change (1 day)
+1.69%
52-Week Range
GBX12.00 - GBX37.00
All Time High
GBX457.50
About

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more